Nisha A. Mohindra, MD
Although advancements have been made in the treatment of patients with stage IIIa non–small cell lung cancer (NSCLC), there is still debate what the optimal therapy is and when it should be administered, according to Nisha A. Mohindra, MD.
In an interview with OncLive® during the 2018 State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Mohindra discussed the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.
OncLive®: What are the optimal treatment approaches for patients with stage IIIa NSCLC?
Mohindra: When it comes to the disease of stage IIIa NSCLC, the question is, “Is this someone who is potentially resectable?” In such a patient, there’s still uncertainty as to whether the approach should be chemotherapy followed by surgery versus chemoradiation followed by surgery. As such, the best approach is to always discuss the patient at a tumor board and get a consensus as to what should be done up front before you start any treatment.
For patients who can’t go through surgery or their disease is too bulky, we will do chemoradiation, and the durvalumab (Imfinzi) data collected from the PACIFIC trial have been exciting for those patients who are treated with chemoradiation.
Could you focus on some historic trials in this area?
A lot of the historic trials asked different questions. We know that if you’re going to consider surgery in the stage IIIa space, you should start with some type of preoperative therapy. There have been a lot of questions, such as, “Does that include radiation? Does that include chemotherapy? Does that include both?
... to read the full story